Skip to main content U.S. flag
          An official website of the United States government
            Here’s how you know
          Here's how you know **The .gov means it’s official.**
                
                Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure
                you’re on a federal government site.
 **The site is secure.**
                
                The **https://** ensures that you are connecting to the official website and that any
                information you provide is encrypted and transmitted securely.


NCD Logo
    
    NCD.gov
          National Council on Disability
        An independent federal agency committed to disability policy leadership since 1978
 Menu


close About the Council
              Misson
                
                Council Members
                
                Council Staff
                
                Email Directory
                
                Council Meetings
                
                Feedback
          
        
          
            
            
            Newsroom
            
        
          
            
            Policy Advice
              Letters
                
                Reports
                
                Testimony
                
                Toolkits
                
                Progress Reports
                
                Frameworks
                
                Fact Sheets
                
                Resources
                
                FAQ
          
        
          
            
            Policy Areas
              Civil Rights
                
                CRPD
                
                Cultural Diversity
                
                Education
                
                Emergency Management
                
                Employment
                
                Financial Assistance and Incentives
                
                Health Care
                
                Housing
                
                International
                
                Long Term Services and Support
                
                Technology
                
                Transportation
                
                Youth Perspectives Font Size:
 A
      Font Size Normal
 A
      Font Size Large
 twitter logoTwitter
 instagram logoInstagram
 linkedin logoLinkedIn
 facebook logoFacebook
 youtube logoYoutube
 Contact Us
          
          Accountability Search small
      Search


NCD Letter to Congress recommending QALY ban in Build Back Better Act Friday, November 12, 2021
 
 The Honorable Charles Schumer
Majority Leader
United States Senate
S-220, U.S. Capitol
Washington, D.C. 20510 The Honorable Nancy Pelosi
Speaker of the House
United States House of Representatives
H-232, U.S. Capitol
Washington, D.C. 20515 The Honorable Steny Hoyer
Majority Leader
United States House of Representatives
H-107, U.S. Capitol
Washington, DC 20515 RE:     Advising policymakers to include language a provision in the Build Back Better Act (H.R. 5367) that explicitly bans the use of QALYs Dear Senate Majority Leader Schumer, Speaker Pelosi, and Majority Leader Hoyer: I write on behalf of the National Council on Disability (NCD), as your federal disability policy advisor, to strongly encourage the inclusion of an unambiguous ban on the quality adjusted life year (QALY) within the text of the Build Back Better Act (H.R. 5367) and located within the bill text in such a way as to convey unequivocal application to the entire Sec. 1194. “Negotiation and Renegotiation Process,” by its addition to the end of the section. Consistent with our advice regarding the discriminatory nature of the QALY for people with disabilities and chronic illnesses, as documented in our 2019 report, *Quality-Adjusted Life Years and the Devaluation of Life with a Disability,*[[i]](https://ncd.gov/publications/2021/ncd-letter-qaly-ban#_edn1) I further encourage you to utilize the reconciliation package as an opportunity to expressly prohibit the use of the QALY by Medicaid and Medicare. Since our initial advice to Congress in our 2019 report, NCD has consistently communicated our concerns with use of the QALY in letters to Committee leadership with jurisdiction over H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act, as well as to the Congressional Budget Office regarding their assessment of H.R. 3, which dismissed concerns about the discriminatory design and impact of the QALY.[[ii]](https://ncd.gov/publications/2021/ncd-letter-qaly-ban#_edn2) In NCD’s *Quality-Adjusted Life Years* report, NCD documents sufficient evidence of the discriminatory design and impact of the QALY to warrant concern and recommend its prohibition. Our recommendation is based on issues raised by bioethicists, patient rights groups, and disability rights advocates; compelling arguments from prominent bioethicists condemning the use of the QALY; and the inability of patients with disabilities to access life-sustaining, lifesaving, and life-changing medications in countries where the QALY is used.[[iii]](https://ncd.gov/publications/2021/ncd-letter-qaly-ban#_edn3) As we document in our 2019 report, it is both the QALY’s discriminatory design and impact that have resulted in its rejection in the U.S. in the past. When Oregon attempted to use the QALY in its Medicaid plan in the 1990s, CMS rejected the plan, finding it violated the Americans with Disabilities Act.[[iv]](https://ncd.gov/publications/2021/ncd-letter-qaly-ban#_edn4) The history of restricted access occurring in countries utilizing QALY-based cost effectiveness research raised concerns that its use in the U.S. would result in rationing care to seniors and people with disabilities, leading Congress in 2009 to prohibit its use under the Affordable Care Act of 2010 (ACA).[[v]](https://ncd.gov/publications/2021/ncd-letter-qaly-ban#_edn5) We encourage you to return to the language utilized in the ACA, which prohibited or severely limited certain federal agencies in their utilization of the QALY, within the text of the Build Back Better Act. That language stated that the Secretary of the U.S. Department of Health and Human Services “shall not use evidence or findings from comparative clinical effectiveness research conducted under section 1181 in determining coverage, reimbursement, or incentive programs under title XVIII in a manner that treats extending the life of an elderly, disabled, or terminally ill individual as of lower value than extending the life of an individual who is younger, nondisabled, or not terminally ill,” and instructed that the Patient-Centered Outcomes Research Institute (PCORI) “shall not develop or employ a dollars per-quality adjusted life year (or similar measure that discounts the value of a life because of an individual’s disability) as a threshold to establish what type of health care is cost effective or recommended.”[[vi]](https://ncd.gov/publications/2021/ncd-letter-qaly-ban#_edn6) We unequivocally agree that drug prices need to be lowered, as high drug prices can themselves be a source of health inequity for people with disabilities. However, their lowering should not be based on the use of a pricing methodology that devalues the lives of people with disabilities in its design and has been proven to be discriminatory in its impact in access to treatments for people with disabilities and chronic illnesses. Neither outright use of the QALY or acceptance of foreign drug prices set in reliance on the QALY method that effectively endorses the use of this discriminatory pricing methodology are acceptable for this reason. NCD welcomes further opportunity to discuss our concerns and discuss our 2019 report with your staff. If this is of interest, please contact NCD’s Executive Director, Anne Sommers McIntosh (amcintosh@ncd.gov) and NCD’s General Counsel and Director of Policy, Joan Durocher (jdurocher@ncd.gov) to arrange a meeting. Respectfully, Andrés J. Gallegos
Chairman  [[i]](https://ncd.gov/publications/2021/ncd-letter-qaly-ban#_ednref1) National Council on Disability, “Quality-Adjusted Life Years and the Devaluation of Life with a Disability” (2019), available at /assets/uploads/docs/ncd-quality-adjusted-life-report-508.pdf. [[ii]](https://ncd.gov/publications/2021/ncd-letter-qaly-ban#_ednref2) CBO’s Model of Drug Price Negotiations Under the Elijah E. Cummings Lower Drug Costs Now Act: Working Paper 2021-01, at 10 (February 4, 2021), available at https://www.cbo.gov/publication/56905 (referencing QALY as, “the best available to CBO and is consistent with the approach taken by many countries to negotiate drug prices.”) [[iii]](https://ncd.gov/publications/2021/ncd-letter-qaly-ban#_ednref3) See footnote 1, *supra;*  also see, NCD’s letter of January 15, 2021, to the Centers for Medicare and Medicaid Services regarding the Most Favored Nation Model Interim Final Rule, available at https://ncd.gov/publications/2021/ncd-letter-cms-most-favored-nation-rule (explaining the discriminatory nature and impact of the QALY and the danger of importing this metric through reliance on foreign drug prices). [[iv]](https://ncd.gov/publications/2021/ncd-letter-qaly-ban#_ednref4) Robert Pear, “White House Expected to Back Oregon’s Health-Care Rationing,” New York Times, March 18, 1993, pg. 00001, https://www.nytimes.com/1993/03/18/us/white-house-expected-to-back-orego.... [[v]](https://ncd.gov/publications/2021/ncd-letter-qaly-ban#_ednref5) See, e.g., statements made during House and Senate debates on health care reform bills in October and November of 2009, expressing concern that U.S. use of cost-effectiveness research, like that utilized in the United Kingdom and Canada, would result in rationing care similar to that experienced by patients in those countries: Senator Kyl (AZ). Congressional Record 155:142 (October 5, 2009) p. S10081; Senator McConnell (KY). Congressional Record 155:19 (October 28, 2009) p. S25860; Senator Kyl (AZ). Congressional Record 155:161 (November 2, 2009) p. S10970; Representative Broun (GA). Congressional Record 155:162 (November 3, 2009) p. H12274; Representative Pitts (PA). Congressional Record 155:163 (November 4, 2009) p. H12293; Senator Roberts (KS). Congressional Record 155:173 (November 20, 2009) p. S11888. [[vi]](https://ncd.gov/publications/2021/ncd-letter-qaly-ban#_ednref6) 42 U.S. Code § 1320e–1 - Limitations on certain uses of comparative clinical effectiveness research.


Budget and Performance Congressional Budget Justification
            
            Financial Audits
            
            Buy American Act
            
            Government Performance and Results Act
 Resources Bylaws
            
            Strategic Plan
            
            Authorizing Statute
 Agency Governance News
            
            FOIA
            
            Contact NCD
            
            Subscribe for NCD News
 Policies / Statements No FEAR Act Data
            
            Vulnerability Disclosure Policy
            
            View accessibility statement
            
            View Equity Action Plan


twitter logoTwitter
 instagram logoInstagram
 linkedin logoLinkedIn
 facebook logoFacebook
 youtube logoYoutube
 
 Phone


NCD.gov
        An official website of the
          National Council on Disability